Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
about
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilastCilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.Psychological factors in asthmaEpidermal growth factor receptor copy number in potentially malignant oral disorders and oral squamous cell carcinoma: a short communication and preliminary study.Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine.Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cellsDoxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease.Caffeine and rolipram affect Smad signalling and TGF-β1 stimulated CTGF and transgelin expression in lung epithelial cells.Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a.Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease.Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.PGC-1α induction in pulmonary arterial hypertensionEmerging drugs for the treatment of chronic obstructive pulmonary disease.Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease.Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokinesNovel medications for asthma: a look at the future.Autocrine Acetylcholine, Induced by IL-17A via NFκB and ERK1/2 Pathway Activation, Promotes MUC5AC and IL-8 Synthesis in Bronchial Epithelial Cells.Treating COPD with PDE 4 inhibitors.Is 'GOLD' standard for the management of COPD in clinical practice?Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.IL-33 stimulates CXCL8/IL-8 secretion in goblet cells but not normally differentiated airway cells.Apigenin and Wogonin Regulate Epidermal Growth Factor Receptor Signaling Pathway Involved in MUC5AC Mucin Gene Expression and Production from Cultured Airway Epithelial Cells.New therapeutic options in the management of COPD - focus on roflumilast.Genetic basis for personalized medicine in asthma.Phosphodiesterase-4 inhibitor therapy for lung diseases.Multiple facets of cAMP signalling and physiological impact: cAMP compartmentalization in the lung.Targeting mucus hypersecretion: new therapeutic opportunities for COPD?Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.NPS2143 Inhibits MUC5AC and Proinflammatory Mediators in Cigarette Smoke Extract (CSE)-Stimulated Human Airway Epithelial Cells.The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.Melatonin inhibits MUC5AC production via suppression of MAPK signaling in human airway epithelial cells.Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.Piclamilast inhibits the pro-apoptotic and anti-proliferative responses of A549 cells exposed to H(2)O(2) via mechanisms involving AP-1 activation.Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.Aclidinium inhibits human lung fibroblast to myofibroblast transition.Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injuryRoflumilast: systemic therapy for chronic obstructive pulmonary disease.
P2860
Q24646836-CE5E66EB-5045-4677-8CA3-61446320A33FQ33258089-752CA6E7-0724-4B02-BAE2-6A2E728C180DQ33799668-4989BD9E-52D0-4C2C-9355-D91C87CF5F29Q33848593-80E242FC-1926-4E87-8151-DFDACE7E66CBQ34195184-98AAD585-10FE-4445-B411-3263856E8B5DQ34464738-186AF2A8-6501-4FDE-8E38-D04F6805CECBQ34920790-762A3FD6-3CE0-41A1-88C4-EC8E67E676EFQ34997202-A84B75DC-6748-47B8-A96D-1E9E5709D019Q35168732-37E0EFB5-3DE4-43E6-8BB0-549046CCFF6AQ35169973-F1B79A41-7A39-4FA5-9A02-AD01126DCF02Q35779864-FCA525C0-31FE-40F0-A992-DA2B59494722Q35987189-EE609ACF-03A8-4306-B24C-6DF40D680838Q36183922-8C432076-1720-4B08-A503-6EF8CFB1FFDAQ36221045-F455F424-4CFE-4D21-A010-03292079D700Q36458412-CC89F057-DE50-4919-854A-36A11CE5548BQ36568745-92296DAE-BAD2-4B4F-822F-2385344205AAQ36648886-8F7CF0A6-E53B-4104-960B-97EF9424FE23Q36821380-DA37FBB3-96B8-4E1E-ADA3-5B5FADC01878Q36958848-6DCC24C7-4129-4ED6-A7A2-6C3A998958ADQ37082594-3C311744-469A-40FE-813C-A387B9EB8408Q37450159-88CA3B18-9A61-4D84-9749-C0B699D395C6Q37681577-CB03F277-CE79-4C1F-B200-FC023E33CC67Q37695423-6BF950D6-FD27-43B5-B9D7-2A36B13F2152Q37695624-4BEBEC25-B418-4C74-8943-EA27FBD1F1C6Q37862085-F8AF019F-34F3-42E1-B6A8-474C0FCFCDE4Q37997823-CD4C9799-3BA8-43EF-8C8A-8FC47988C1FCQ38105165-53B2144F-FBFF-4611-94EF-D50F7622BD8DQ38166604-B8C8360C-8253-4DBD-928C-E2248B2A6CDCQ38217069-AE5D66DD-B7AE-4025-B121-23C01C867E56Q38681962-E388E407-EAD0-4177-A51D-087BEF33863DQ38730058-9E0E5F41-C31E-4BC8-9463-80DCC741A30FQ38832398-FDFAAD3E-60E3-4405-B8FD-789E4E23E029Q39005577-C863E38A-CD70-4E44-A7DF-A3D8C77290E9Q39035070-1872394F-344F-423C-9582-94E996E47E8FQ39322017-69404077-7846-4770-B5D4-A371BD4B51D7Q39391414-D82132D8-5243-4A62-9CB9-C4A10A944291Q40024513-0C0546F7-55BB-4E85-8D2E-7C1BF81A60BFQ41252525-72EB5F0E-A8CC-4FBF-860D-EE6C4D300198Q41429523-ACED58AA-2B35-4634-8F33-4BF0F624F41CQ43061644-7F7E29D1-30E5-4A7D-B751-C72B7C03ECD4
P2860
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@ast
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@en
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@nl
type
label
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@ast
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@en
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@nl
prefLabel
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@ast
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@en
Phosphodiesterase 4 inhibition ...... human airway epithelial cells.
@nl
P2093
P2860
P356
P1433
P1476
Phosphodiesterase 4 inhibition ...... human airway epithelial cells
@en
P2093
P2860
P304
P356
10.1136/THX.2004.025692
P407
P577
2005-02-01T00:00:00Z